05 Sep Scleroderma
Scleroderma also known as systemic sclerosis, is a systemic autoimmune disease characterized by damage to endothelial and smooth muscle cells of the small arteries. Replacement with fibrous material results, and there is an influx of inflammatory cells. Primarily affects skin and joints but can affect the heart and lungs, and digestive tract. Some types of scleroderma are rapidly progressive and deadly. Scleroderma is often treated with immunosuppressive drugs, and there is no known cure. Some investigators are looking at using the regenerative properties of cell therapy to mitigate the impact of scleroderma. Research is ongoing to evaluate the effects of stem cells on auto-immune conditions. As recently stated in Best Practices & Research Clinical Rheumatology in a review of Scleroderma, “Stem cell transplantation seems to be promising in restarting the immune system to diminish fibrosis and restore microvasculature.” Read More…
Scleroderma and Cell Surgical Network
CELL SURGICAL NETWORK has developed a specific SVF deployment protocol that attempts to utilize the immuno-regulatory and anti-inflammatory properties of SVF (rich in mesenchymal stem cells and growth factors) to mitigate the effects of scleroderma. SVF is deployed systemically and may require repeat dosing. This is done as an outpatient at the time of SVF harvesting and procurement. The entire cellular surgical procedure takes approximately three hours.
Scleroderma Call to Action
We care about our Scleroderma patients at Cell Surgical Network and take pride in the time we provide to our patients to deploy the best protocols to help our patients achieve their goals. By filling out Confidential Candidate Application, we will answer all of the questions and concerns you may have about Cell Surgical Network protocols for Scleroderma. Our Cell Surgical Network has Treatment Centers in several states, checkout our Physician Network to find the closest Treatment Center Our Physician Network Map